Last checked at 16 Feb 2016 07:00
ValiRx Plc
("ValiRx" or "the Company")
VAL201 CLINICAL TRIAL UPDATE
Cohort Review Committee - Final dose escalation approved.
London, UK, 16th February 2016: ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, provides a clinical trial update.
Closely following the quarterly update released on 9 February 2016, ValiRx announces that a further cohort of subjects have successfully completed the core part of their clinical trial dosing sequence with no significant adverse events being reported among the participants. In light of this, the trial's Cohort Review Committee has recommended that the final dose escalation be approved.
The trial itself continues according to its approved design and its schedule is on time. Further updates and information will be provided during the dose expansion phase, during which the specific tumour modulating effects that were shown preclinically and have been hinted at during the in-human stage, are being specifically investigated. Safety and tolerability throughout the trial will continue to be paramount.
The Company believes that being able to dose patients at levels and with a frequency that matches the pre-clinical validated amounts that are therapeutically relevant, represents another important milestone.
*** ENDS ***
For more information, please contact:
ValiRx plc | Tel: +44 (0) 20 3008 4416 |
Dr Satu Vainikka, Chief Executive | www.valirx.com |
Tarquin Edwards, Head of Communications. | Tel: +44 (0) 7879 458 364 |
tarquin.edwards@valirx.com | |
Cairn Financial Advisers LLP (Nominated Adviser) | Tel: +44 (0) 20 7148 7900 |
Liam Murray / Avi Robinson | |
Northland Capital Partners Limited (Broker) | Tel: +44 (0) 20 7382 1100 |
Patrick Claridge / David Hignell (Corporate Finance) | |
John Howes / Abigail Wayne (Broking) |
About ValiRx Plc
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.
The Company listed on the Alternative Investment Market ("AIM") of the London Stock Exchange in October 2006.
The Company has a pipeline of other therapeutic drugs, which are currently progressing towards clinical trials. The product focus is in the targeted analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases. It actively manages projects within its portfolio as a trading company. The ValiRx business model spreads the risks of life science technology development by minimizing financial exposure and running a set of projects to defined commercial endpoints. This maximizes returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.
The Company operates through the following divisional companies:
1. ValiPharma is the therapeutics division, with two embedded technologies primarily directed at the treatment of cancers.
2. ValiFinn is the biomarkers and diagnostic development division. ValiRx acquired through its ValiFinn subsidiary, the complimentary TRAC technology to strengthen the portfolio.
3. ValiSeek is a joint venture between ValiRx and Tangent Ltd to develop Val401 in lung cancer and potentially other indications.